Home > Back to Publisher > Report Information

The Global Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape

Arrowhead Publishers
May 17, 2007
186 Pages - SKU: AH1513757

Abstract Table of Contents Search inside this report Related Reports

The global anti-infective market is currently valued at US$66.5 billion with antiviral agents accounting for 24% of sales (excluding vaccines which target viral infectious diseases).

According to Arrowhead Publishers’ new report The Antivirals Market: R&D Pipelines, Markey Analysis and Competitive Landscape, the anti-viral market will be driven by the uptake of newer anti-retroviral agents in combination therapy and the launch of ten new products for the treatment of HIV and hepatitis which will address the need of treatment-resistant patients. This will help to stem the tide of this prevalent and often lethal killer in our society today.

Pharmaceutical companies continue to develop a new generation of antiretroviral agents to overcome the issue of drug and cross-resistance. Meanwhile new drug classes are under evaluation that increases the virologists armory against these endemic and often deadly infectious diseases.

This report examines each of the antiviral classes in turn, assessing the market potential and encompassing the major infectious diseases to which they are applicable.

The following product classes are analyzed in this report:

antisense
attachment, entry and fusion inhibitors
DNA polymerase inhibitors
integrase inhibitors
interferons
maturation inhibitors
monoclonal antibodies
neuraminidase inhibitors
NS3 protease inhibitors
nucleoside reverse transcriptase inhibitors
nucleotide reverse transcriptase inhibitors
protease inhibitors
reverse transcriptase inhibitors
RNA polymerase inhibitors

The report assesses the overall antiviral market, key classes, the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation by category and by leading players, therapies and their products and analyzes market trends.

The report examines promising pipeline products and their potential impact on the prescription of current and new antiviral agents and the future antiviral market.

Key features of this report:

Overview of the antiviral market, including main infectious agents, therapeutic drug classes and key players.
In-depth analysis of different classes of antiviral agents, including key antiretroviral and antiviral agents and compares drugs within each class.
Comprehensive facts and figures for the antiviral market, including main players and therapeutic break-downs.
Future trends in the antiviral marketplace, driven by drug resistance, cross-resistance and patient demographics.
Outlook for the antiviral market, including the emergence of novel therapies, new combination therapies and the impact of generics.

1 EXECUTIVE SUMMARY
2 INTRODUCTION TO INFECTIOUS DISEASES: 2.1 Cytomegalovirus (CMV); 2.2 Hepatitis B virus (HBV); 2.3 Hepatitis C Virus (HCV); 2.4 Herpes Simplex Virus (HSV); 2.5 Human Immunodeficiency Virus (HIV); 2.6 Influenza (Flu); 2.7 Respiratory Syncytial Virus (RSV)
3 PATIENT DEMOGRAPHICS: 3.1 Cytomegalovirus Patient Statistics; 3.2 Hepatitis B Patient Statistics; 3.3 Hepatitis C Patient Statistics; 3.4 Herpes Simplex Patient Statistics; 3.5 Human Immunodeficiency Patient Statistics; 3.6 Influenza Patient Statistics; 3.7 Respiratory Syncytial Patient Statistics
4 KEY DRIVERS: 4.1 Drug Resistance; 4.2 Cross-Resistance; 4.3 New treatments; 4.4 Combination therapy; 4.5 Improvements in diagnosis; 4.6 Vaccines; 4.7 Potential for clinical success; 4.8 Indirect cost associated with infectious diseases
5 KEY RESISTORS: 5.1 Cost-benefit of prophylactic therapy or antiviral therapy; 5.2 Treatment availability; 5.3 Patient demographics; 5.4 Generics; 5.5 Curative Therapies and Vaccines; 5.6 Diagnosis
6 THE MARKET: 6.1 The Global Anti-Infective Market; 6.2 Market Segments; 6.3 Global Anti-Viral Market; 6.4 The Major Players; 6.5 Market Trends
7 LEADING DRUG CLASSES: 7.1 Antisense; 7.2 DNA Polymerase Inhibitors; 7.3 Interferons; 7.4 Fusion Inhibitors; 7.5 Neuraminidase Inhibitors; 7.6 Reverse Transcriptase Inhibitors; 7.7 RNA Polymerase Inhibitors; 7.8 Protease Inhibitors; 7.9 Uncoating Inhibitors
8 LEADING BRANDS: 8.1 Antisense; 8.2 DNA Polymerase Inhibitors; 8.3 RNA Polymerase Inhibitors; 8.4 Fusion Inhibitors; 8.5 Inteferons; 8.6 Monoclonal Antibodies; 8.7 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); 8.8 Nucleoside Reverse Transcriptase Inhibitors (NRTIs); 8.9 Nucleotide Reverse Transcriptase Inhibitors (NtRTIs); 8.10 Protease Inhibitors; 8.11 Neuraminidase Inhibitors (NIs); 8.12 Global Anti-Viral Sales Forecasts
9 FUTURE BRANDS: 9.1 Attachment, Entry and Fusion Inhibitors; 9.1. Ongoing pivotal Phase II/III Maraviroc trails; 9.1. Safety Profile of Vicriviroc; 9.2 Integrase Inhibitors; 9.3 Interferons; 9.4 Maturation Inhibitors; 9.5 Non-Nucleoside Reverse Transcriptase Inhibitors; 9.6 Nucleoside Reverse Transcriptase Inhibitors; 9.7 Protease Inhibitors; 9.8 NS3 Protease Inhibitors; 9.9 Polymerase Inhibitors; 9.10 Global Sales Forecasts for New Anti-Viral Agents; 9.11 The Future of the Antiviral Market
10 APPENDIX 1 - PHARMACEUTICAL COMPANIES: Abbott Laboratories; AstraZeneca AB; Boehringer Ingelheim Corporation; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Johnson & Johnson,; Merck & Co Inc; Novartis International AG; Pfizer Inc; Roche
11 APPENDIX 2 - BIOTECHNOLOGY AND BIOPHARMACEUTICAL COMPANY PROFILES: 11.1 Achillon Pharmaceuticals; 11.2 Agouron Pharmaceuticals (A Pfizer subsidiary); 11.2 Genzyme; 11.3 ISIS Pharmaceuticals; 11.4 MEDIVIR AB; 11.5 Panacos; 11.6 Pharmasset, Inc.; 11.7 Progenics Pharmaceuticals, Inc.; 11.8 Tanox; 11.9 Tibotec; 11.10 Trimeris, Inc.; 11.11 Vertex Pharmaceuticals
12 APPENDIX 3: 12.1 Bibliography
TABLES: Table 2.1: Infectious Disease Leading Worldwide Health Burden; Table 3.1: Worldwide Prevalence of HCV; Table 4.1. Potential for clinical success; Table 6.1: Historical Sales of 30 Leading Anti-infective Brands US$ million (2001-2005); Table 8.1. Infectious Agent Treatment Options; Table 8.2: Sales Forecasts of Antisense Products US$m 2005A - 2012E; Table 8.3: Comparison of the Leading DNA Polymerase Inhibitor Brands for the Treatment of CMV; Table 8.4: Comparison of the Leading DNA Polymerase Inhibitor Brands for the Treatment of HSV; Table 8.5: Sales Forecasts of DNA Polymerase Inhibitors (US$m) 2005A - 2012E; Table 8.6: Sales Forecasts of RNA Polymerase Inhibitors 2005A - 2012E; Table 8.7: Sales Forecasts of Fusion Inhibitors (US$m) 2005A - 2012E; Table 8.8: Comparison of the Leading Interferon Monotherapies Approved for Hepatitis; Table 8.9: Comparison of the Leading Interferon Combination Therapies Approved for Hepatitis; Table 8.10: Sales Forecasts of Interferons (US$m) 2005A - 2012E; Table 8.11: Sales Forecasts of Monoclonal Antibodies (US$m) 2005A - 2012E; Table 8.12: Comparison of the Leading NNRTIs; Table 8.13: Sales Forecasts of NNRTIs (US$m) 2005A - 2012E; Table 8.14: Comparison of the Leading NRTI Approved for HBV; Table 8.15: Comparison of the Leading NRTIs Approved for HIV Monotherapy; Table 8.16: Comparison of the Leading NRTI Combination Therapies Approved for HIV; Table 8.17: Sales Forecasts of NRTIs (US$m) 2005A - 2012E; Table 8.18: Comparison of the Leading NtRTIs Brands; Table 8.19: Sales Forecasts of NtRTIs (US$m) 2005A - 2012E; Table 8.20: Comparison of the Leading PI Brands - Single Agents; Table 8.21: The Leading Combination PI Brand; Table 8.22: Sales Forecasts of PIs (US$m) 2005A - 2012E; Table 8.23: Leading NIs Approved for Influenza; Table 8.24: Sales Forecasts of NIs (US$m) 2005A - 2012E; Table 8.25: Sales Summary of Antiviral Agents (US$m) 2005A - 2012E; Table 9.1 Reduction of Viral Load Following Treatment with GS 0137; Table 9.2: Reduction of Viral Load Following Treatment with TNC125; Table 9.3: Sales Summary of New AntiViral Agents (US$m) 2005A - 2012E; Table 9.4 Sales Summary of New Antiviral Agents (US$m) 2005A - 2012E
FIGURES: Figure 2.1 Schematic of influenza virus; Figure 3.1 Geographic Distribution of Chronic HBV Infection; Figure 6.1 Global Anti-Infective Market US$66.5 bn (2006); Figure 6.2 Global Anti-Infective Market US$100 bn (2015); Figure 6.3 Antiretroviral Agents US$9.7 bn - Drug Class Split (2006); Figure 6.4 Hepatitis Antiviral Agents US$3.8 bn - Drug Class Split (2006); Figure 6.5 Other Antiviral Agents US$6.4 bn - Therapy Class Split (2006); Figure 6.6 The Major Players (2006); Figure 6.7 The Major Players (2012); Figure 6.8 The Global Antiviral Market (2012); Figure 6.9 Antiretroviral Agents US$12.6 bn - Drug Class Split (2012); Figure 6.10 Antiviral Agents US$5.5 bn - Drug Class Split (2012); Figure 6.11 Other Antiviral Agents US$5.6 bn - Therapy Class Split (2012); Figure 7.1 Site of Action of Leading Antiviral Agents; Figure 8.1 Clinical Efficacy in TORO 1 & 2 Studies; Figure 8.2 Global HCV Therapy; Figure 9.1 Structure of Maraviroc; Figure 9.2 Clinical Efficacy of TNX-355; Figure 9.3 Virologic Response to TNX-355; Figure 9.4 Pharmacokinetics of TRI-1144 in Rat Models; Figure 9.5 Pharmokinetics of TRI-999 formulations in Rat Models; Figure 9.6 Clinical Efficacy of Vicriviroc; Figure 9.7 Clinical Efficacy of Vicriviroc in Sub Populations; Figure 9.8 Clinical Efficacy of MK0518; Figure 9.9 Schematic of Albuferon’s Structure; Figure 9.10 Phase II Pharmacokinetic Profile of Albuferon; Figure 9.11 (+)-Calanolide A Structure; Figure 9.12 Clinical Efficacy of Racivir; Figure 9.13 Clinical Efficacy of Racivir; Figure 9.14 Phase I Clinical Efficacy of Racivir; Figure 9.15 Clinical Efficacy of Valopicitabine; Figure 9.16 Clinical Efficacy of Valopicitabine; Figure 11.1 Medivir AB Pipeline; Figure 11.2 Pharmassett Pipeline; Figure 11.3 Progenics Pipeline; Figure 11.4 Tanox Pipeline; Figure 11.5 Vertex Pipeline

The Global Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape

Share this report

Other tasks

Research Assistance

Related Markets

Research & Development Reports

Free Alert Me service